Clinical trials: Neoplasia Prostate
Prostate Cancer, Non-metastatic Prostate Cancer
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
Men diagnosed with significant cancer confined to the prostate currently undergo radical therapy directed to the whole prostate (radiotherapy or prostatectomy).
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP4-CHRONOS (NCT04049747)
- Testing
- Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], Focal therapy, Focal therapy after Finasteride 5Mg tablets for 12 weeks
- Where
- 10 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
- Trial name
- NCT01419717
- Testing
- Denosumab
- Where
- 64 sites in Argentina, Austria and 17 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
This is a single arm study of 11 men with treatment refractory metastatic Castrate Resistant Prostate Cancer (CRPC) who will receive temsirolimus IV at a dose of 25 mg weekly until progression.
- Trial name
- NCT00887640
- Testing
- Temsirolimus, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Prostate Cancer
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.
- Trial name
- NCT02135484
- Testing
- Alpharadin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone.
- Trial name
- NCT01828476
- Testing
- Abiraterone, ABT-263, Hydroxychloroquine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Protection of Rectum From High Radiation Doses
The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.
- Trial name
- NCT01601691
- Testing
- DuraSeal
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- University of Oulu
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Refractory Prostate Cancer
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis…
- Trial name
- NCT00286091
- Testing
- Denosumab
- Volunteers
- 1,435 people
- Sponsor
- Amgen
Prostate Cancer
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00433446
- Testing
- CNTO 328
- Where
- 123 sites in United States
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC)…
- Trial name
- NCT03148795
- Testing
- Talazoparib
- Where
- 120 sites in United States, Australia and 12 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Prostate Cancer
Improving Germline Testing in At-Risk Patients With Prostate Cancer
A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational session.
- Trial name
- IMPRINT (NCT05470036)
- Testing
- Educational intervention.
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Prostate Cancer
Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to <1.0 ng/ml at 3…
- Trial name
- Nexrutine (NCT01705652)
- Testing
- Nexrutine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior…
- Trial name
- NCT01790126
- Testing
- ARN-509, LHRH Agonist
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
- Trial name
- NCT01071915
- Testing
- Degarelix 240/80 mg
- Where
- 11 sites in South Korea
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior…
- Trial name
- PORTER (NCT03835533)
- Testing
- NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B)
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Parker Institute for Cancer Immunotherapy
Prostate Cancer
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in men. Patients with recurrent or metastatic prostate cancer are treated with androgen-deprivation therapy, often termed castration therapy.
- Trial name
- NCT01620593
- Testing
- Metformin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab…
- Trial name
- PRO-MERIT (NCT04382898)
- Testing
- BNT112, Cemiplimab
- Where
- 22 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Prostate Cancer
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00348816
- Testing
- docetaxel, prednisone, Radical prostatectomy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.